This opportunity is no longer accepting applications.
grant

Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

RFA-HL-23-011

The Catalyze Product Definition Funding Opportunity is designed to support early-stage research to discover and assess potential treatments for heart, lung, blood, and sleep diseases. This grant is part of the Catalyze initiative, aiming to advance projects to a stage where they can join a preclinical program or attract separate development funding from federal or private partners.

This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze i…

Funding Source

Agency: National Heart, Lung, and Blood Institute
Sub-agency: National Institutes of Health

Dates

Opportunity Released: January 24, 2022
Open for Submission: January 24, 2022
Submission Deadline: December 20, 2024
Application Window Closes: December 20, 2024

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.